Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on February 21, 2018. The report details a new statement of work entered into with AGC Biologics (formerly CMC ICOS Biologics, Inc.) under an existing development and manufacturing services agreement dated May 20, 2016.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the new contract:
- Total Contract Value: Approximately $5.6 million in payments.
- Payment Conditions: Subject to the completion of applicable work stages.
Material Changes
The material event reported is the engagement of AGC Biologics for the process transfer and commercial scale cGMP manufacturing of CB 2679d, a highly potent next-generation coagulation Factor IX (FIX) variant for severe hemophilia B. This represents a significant step in the commercialization preparation for the company's lead asset.
Outlook, Risks, and Unusual Items
Agreement Terms: The initial term is ten years or until all stages under outstanding statements of work are completed, whichever is later.
Termination Rights:
- Either party may terminate for material uncured breach or bankruptcy.
- The Company may terminate for any reason upon prior notice.
- Either party may terminate if manufacturing development activities cannot be completed for technical or scientific reasons.
Risks: The agreement is contingent on technical and scientific feasibility. If manufacturing development fails, the agreement may be terminated.
Investor Verification Checklist
- Verify the current development status of CB 2679d and the timeline for process transfer.
- Confirm the specific milestones required to trigger the $5.6 million in payments.
- Assess the financial impact of the $5.6 million commitment against the company's current cash position (not provided in this filing).
- Monitor for any future disclosures regarding technical or scientific challenges that could trigger termination.